The Roche Group and the Islamic Republic of Mauritania’s Ministry of Health have signed a partnership agreement enabling access to Roche’s innovative
On Monday 16 May 2011 in Basel, Switzerland, the pharmaceutical group Roche and the Islamic Republic of Mauritania’s Ministry of Health signed an Access Program for Roche’s innovative treatments aimed at low-income patients who lack medical insurance. The agreement will enable the Mauritanian government to offer hundreds of patients free, complete access to Roche’s most innovative medicines in the therapeutic areas of oncology, viral hepatitis, kidney failure and rheumatoid arthritis.
The agreement was signed by Mr. Ba Housseynou Hamady, the Mauritanian Minister of Health, and Mr. Sami Zerelli, General Manager of Roche for North and West Africa, in the presence of Mr. André Hoffman, Vice president of the F. Hoffman-La Roche Group.
“Mauritania is a country which is putting the health of its citizens at the top of its priorities. This initiative will allow economically disadvantaged patients to have access to new differentiated treatments,” said Sami Zerelli. “This partnership will also enable training of healthcare professionals in Mauritania who will be able to benefit from the scientific and medical experience of the Roche Group.”
About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80’000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com
